This gene encodes a transmembrane protein belonging to a family of proteins containing TLC domains, which are postulated to function in lipid synthesis, transport, or sensing. The protein localizes to the endoplasmic reticulum (ER), and may recycle between the ER and ER-Golgi intermediate compartment.[2]
↑Ranta S, Zhang Y, Ross B, Lonka L, Takkunen E, Messer A, Sharp J, Wheeler R, Kusumi K, Mole S, Liu W, Soares MB, Bonaldo MF, Hirvasniemi A, de la Chapelle A, Gilliam TC, Lehesjoki AE (Oct 1999). "The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8". Nat Genet. 23 (2): 233–6. doi:10.1038/13868. PMID10508524.
Ranta S, Lehesjoki AE (2001). "Northern epilepsy, a new member of the NCL family". Neurol. Sci. 21 (3 Suppl): S43–7. doi:10.1007/s100720070039. PMID11073227.
Winter E, Ponting CP (2002). "TRAM, LAG1 and CLN8: members of a novel family of lipid-sensing domains?". Trends Biochem. Sci. 27 (8): 381–3. doi:10.1016/S0968-0004(02)02154-0. PMID12151215.
Ranta S, Lehesjoki AE, Hirvasniemi A, et al. (1996). "Genetic and physical mapping of the progressive epilepsy with mental retardation (EPMR) locus on chromosome 8p". Genome Res. 6 (5): 351–60. doi:10.1101/gr.6.5.351. PMID8743986.
Lonka L, Kyttälä A, Ranta S, et al. (2000). "The neuronal ceroid lipofuscinosis CLN8 membrane protein is a resident of the endoplasmic reticulum". Hum. Mol. Genet. 9 (11): 1691–7. doi:10.1093/hmg/9.11.1691. PMID10861296.
Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID14702039.
Ranta S, Topcu M, Tegelberg S, et al. (2004). "Variant late infantile neuronal ceroid lipofuscinosis in a subset of Turkish patients is allelic to Northern epilepsy". Hum. Mutat. 23 (4): 300–5. doi:10.1002/humu.20018. PMID15024724. replacement character in |first4= at position 2 (help); replacement character in |last5= at position 1 (help)
Hermansson M, Käkelä R, Berghäll M, et al. (2005). "Mass spectrometric analysis reveals changes in phospholipid, neutral sphingolipid and sulfatide molecular species in progressive epilepsy with mental retardation, EPMR, brain: a case study". J. Neurochem. 95 (3): 609–17. doi:10.1111/j.1471-4159.2005.03376.x. PMID16086686.